Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study
| Autor: | Carlo Alfieri, Pietro Lampertico, Mohamed Gendia, Piergiorgio Messa, Maria Teresa Gandolfo, Roberta D'Ambrosio, Fabrizio Fabrizi, Maria Rosaria Campise |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Sustained Virologic Response Hepatitis C virus Hepacivirus Kidney medicine.disease_cause Antiviral Agents Gastroenterology Group A Group B Simeprevir Internal medicine medicine Humans Kidney transplantation Retrospective Studies Transplantation Proteinuria business.industry virus diseases Retrospective cohort study Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Kidney Transplantation digestive system diseases medicine.anatomical_structure Liver Disease Progression Kidney Failure Chronic Drug Therapy Combination Female Patient Safety Sofosbuvir medicine.symptom business |
| Zdroj: | Transplant International. 32:493-501 |
| ISSN: | 1432-2277 0934-0874 |
| Popis: | Hepatitis C virus (HCV) in kidney transplanted patients (KTx-p) carries a high risk for a worse outcome. This retrospective study evaluates the impact of HCV and of the new direct acting antivirals (DAAs) on patient and graft outcomes in KTx patients. Forty (6.5%) of the 616 KTx-p, who received a kidney transplantation (KTx) in our Centre had antibodies against HCV: 13 were positive for HCV RNA and received DAAs (Group A); 11 were HCV RNA positive and did not receive any treatment (Group B; n = 11); 16 were negative for HCV RNA (Group C). All Group A patients had HCV RNA negativity after 12 weeks of treatment, and 12 (92.30%) achieved a sustained virological response (SVR). Only two patients, who had proteinuria greater than 500 mg/day showed a worsening of proteinuria after antiviral therapy in Group A. Liver enzyme elevation and death were significantly more frequent in Group B than other groups. Our results support the notion that active HCV infection negatively affects kidney recipients and that DAA have a high safety and efficacy profile after KTx with no significant negative effect on allograft function, particularly in well-functioning renal grafts. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text